Bristol Myers’ price target rose to $40 from $37 at Morgan Stanley


Morgan Stanley analyst Terence Flynn raised the firm’s target price in Bristol Myers (BMY) to $40 from $37 and maintains an underweight rating on the stock. 2026 revenue and EPS guidance came in above consensus, but was driven by higher-than-expected Eliquis guidance, the analyst tells investors in a research note.

Claim 50% off TipRanks Premium

Posted first The Fly – The ultimate source of real-time, breaking financial news that moves the market. Try now >>

Check out today’s top performing stocks on TipRanks >>

Read more about BMY:

Disclaimer and DisclosureReport a problem



Source link

  • Related Posts

    Bangladesh is voting in the world’s first Gen Z-inspired election

    Bangladesh is voting in the world’s first Gen Z-inspired election Source link

    Baidu’s ( BIDU ) AI chip spin-off seen as catalyst for shareholder value

    Baidu, Inc. (NASDAQ:BEGINNING) is one of the 10 AI stocks to keep on your radar. On February 4, Tiger Securities US analyst Bo Pei raised their price target on the…

    Leave a Reply

    Your email address will not be published. Required fields are marked *